2024
Risankizumab for Ulcerative Colitis
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J, Parkes G, Peyrin-Biroulet L, D’Haens G, Hisamatsu T, Siegmund B, Wu K, Boland B, Melmed G, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan W, Pivorunas V, Sanchez Gonzalez Y, D’Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus E, Balderramo D, Goncalves S, Lasa J, Novillo A, Ruffinengo O, Heeren S, Reinisch W, Baert F, Bossuyt P, Colard A, Dewit O, Ferrante M, Franchimont D, Louis E, Rahier J, Francesconi C, Kaiser Junior R, Parra R, Sassaki L, Penchev P, Stanchev D, Atkinson K, Beaton M, Bessissow T, Greenbloom S, Lachance J, Lim A, Panaccione R, Samson J, Shulman S, Siffledeen J, Alfaro I, Valenzuela C, Walsen G, An P, Cao Q, Chen Y, Chen Y, Gao X, Hou X, Hu N, Li Y, Liu F, Liu M, Lungen L, Ran Z, Tang T, Wang X, Yang S, Zhan Q, Zhang G, Zhang H, Zhang J, Zhang X, Zhong J, Zou X, Alvarez E, Ricaurte J, Borzan V, Krznaric Z, Puljiz Z, Bortlik M, Svoboda P, Ulbrych J, Vanasek T, Kjeldsen J, Munck L, Poulsen A, Ali E, Salem O, Sawah H, Waked I, Altwegg R, FLAMANT M, Fumery M, Hebuterne X, Laharie D, Peyrin-Biroulet L, Roblin X, Treton X, Atreya R, Deppe H, Hasselblatt P, Kandulski A, Klaus J, Krause T, Kucharzik T, Mertens J, Mross M, Naumann A, Reindl W, Schiefke I, Schreiber S, Schubert S, Siegmund B, Sturm A, Bamias G, Koutroubakis I, Manolakopoulos S, Mantzaris G, Tzouvala M, Viazis N, Avni-Biron I, Goldin E, Katz L, Lahat-Zok A, Segal A, Ardizzone S, Armuzzi A, Cicala M, Colecchia A, Cosintino R, Gasbarrini A, Geccherle A, Giannini E, Gionchetti P, Luzza F, Monteleone G, Privitera A, Saibeni S, Vangeli M, Abe Y, Aoyama N, Asonuma K, Endo Y, Esaki M, Fujii T, Fukuda K, Hirai F, Hisanaga Y, Horiki N, Iguchi M, Ishigami K, Ishiguro Y, Ito H, Kakuta Y, Kamikozuru K, Kato J, Kawanishi T, Kobayashi T, Kuge H, Maemoto A, Masuda T, Matsuoka K, Matsushima K, Matsushima M, Motoya S, Nakai K, Nakajima K, Nakamura M, Nishida A, Nishikawa T, Nishimata N, Ochiai T, Ohmiya N, Ohnishi Y, Oka S, Ozeki K, Saito D, Saruta M, Sasaki M, Shimizu M, Sugimoto K, Sujino T, Suzuki T, Takatori H, Takatsu N, Takedatsu H, Takeuchi K, Tanaka H, Tokito S, Endo T, Toyokawa T, Uenoyama Y, Yamamoto T, Yamamoto T, Yasuda H, Yokoyama K, Derovs A, Pukitis A, Jonaitis L, Kazenaite E, Pinzon Te L, D'Haens G, Lutgens M, Brooker J, Gearry R, Griffiths B, Inns S, Schultz M, Eszyk J, Kierkus J, Kleczkowski D, Kopon A, Petryka R, Regula J, Romanczyk T, Rydzewska-Wyszkowska G, Sikorski P, Talarek M, Cerqueira R, Goncalves T, Lopes S, Ministro P, Portela F, Tavares H, Diculescu M, Goldis A, Seicean A, Agafina A, Edin A, Gerasimova E, Gettueva M, Kashnikov V, Pirmagomedov A, Rafalskiy V, Sharapova K, Smolyarchuk E, Varganova D, Grgov S, Jovanovic I, Svorcan P, Tarabar D, Ling K, Balaz J, Durina J, Gregus M, Laclav M, Drobne D, Deetlefs E, Peter J, Rajabally M, Rosa J, van Zyl J, Wright J, Cheon J, Jang B, Kim J, Kang S, Kim D, Kim T, Kim Y, Lee J, Lee K, Park D, Song G, Arguelles Arias F, Castro Laria L, Echarri Piudo A, Garcia Lopez S, Hernandez Ramirez V, Martin Arranz M, Varela Trastoy P, Vera Mendoza M, Lordal M, Biedermann L, Misselwitz B, Chang C, Chou J, Kuo C, Lin C, Tu C, Alkim H, Erzin Y, Soykan I, Kravchenko T, Tsarynna N, Vyshyvanyuk V, Ahmad T, Cummings F, Kapur K, Kaser A, Kent A, Parkes G, Patel K, Speight R, Steel A, Aberra F, Aguilar H, Al Bawardy B, Ananthakrishnan A, Barnes M, Beck K, Berkelhammer C, Boland B, Bullock J, Chiplunker A, Dalal R, Dalal S, Delgado B, DiGiovanna M, DuVall G, Freedland C, Friedenberg K, Gaidos J, Ginsburg P, Hassanein T, Higgins P, Hong J, Hou J, Huilgol V, Inamdar N, Kapur S, Kerman D, Levine H, Lodhia N, Loftus E, Mayoral J, McNeil D, Melmed G, Mushahwar A, Ojeas H, Patel B, Phillips R, Pouzar J, Sarles H, Schock J, Sedghi S, Shah N, Siddiqui J, Stokesberry D, Su L, Swaminath A, Verma D, Weber J, Younes Z, Zisman T. Risankizumab for Ulcerative Colitis. JAMA 2024, 332: 881-897. PMID: 39037800, PMCID: PMC11264075, DOI: 10.1001/jama.2024.12414.Peer-Reviewed Original ResearchClinical remission rateActive ulcerative colitisRemission rateUlcerative colitisInduction trialsMaintenance trialsClinical centersPhase 3 randomized clinical trialModerately to severely active ulcerative colitisSeverely active ulcerative colitisSafety of risankizumabTreatment of ulcerative colitisHistory of intoleranceMaintenance therapyClinical remissionClinical responseResponse to 1Intravenous treatmentRisankizumabAdverse event signalsConventional therapySubcutaneous treatmentFollow-upPlaceboAdvanced therapies
2023
Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials
AlAmeel T, AlMutairdi A, Al-Bawardy B. Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials. Clinical And Experimental Gastroenterology 2023, 16: 147-167. PMID: 37609124, PMCID: PMC10441644, DOI: 10.2147/ceg.s375969.Peer-Reviewed Original ResearchManagement of UCToll-like receptor 9Ulcerative colitisAdvanced therapiesSubcutaneous tumor necrosis factor (TNF) inhibitorsPhosphodiesterase 4 inhibitor apremilastTumor necrosis factor inhibitorsInnovative clinical trial designsNecrosis factor inhibitorsRecent clinical trialsProgressive inflammatory disorderClinical trial designFurther drug developmentRemission rateBiologic agentsFactor inhibitorsInflammatory disordersTherapeutic armamentariumReceptor 9Clinical trialsAvailable agentsTrial designTherapyColitisDrug developmentEarly Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 2023, 5: otad032. PMID: 37323477, PMCID: PMC10263117, DOI: 10.1093/crocol/otad032.Peer-Reviewed Original ResearchAcute severe ulcerative colitisSevere ulcerative colitisClinical outcomesSigmoidoscopy groupHospital stayFlexible sigmoidoscopyUlcerative colitisIntravenous corticosteroid useRate of colectomyRisk of colectomyHours of admissionOpioid medication useShorter hospital stayCohort of patientsFavorable clinical outcomeLarge prospective studiesRelevant clinical outcomesColectomy rateCorticosteroid useSecondary outcomesMedication usePrimary outcomeProspective studyRetrospective studySigmoidoscopyOral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
Almomen H, Al-Bawardy B. Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation. Inflammatory Bowel Diseases 2023, 29: 837-838. PMID: 36888548, DOI: 10.1093/ibd/izad040.Peer-Reviewed Original Research
2022
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mosli M, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, Khardaly A, AlMolaiki M, Al-Omari B, Albarakati R, Al-Jedai A, Saadah O, Almadi M, Al-Bawardy B. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease. Saudi Journal Of Gastroenterology 2022, 29: s1-s35. PMID: 36412460, PMCID: PMC10540981, DOI: 10.4103/sjg.sjg_277_22.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseManagement of IBDExpert opinion-based recommendationsManagement of adultsOpinion-based recommendationsLevel of evidenceEvidence-based interventionsIBD diagnosisUlcerative colitisCrohn's diseaseConsensus guidelinesConsensus guidanceOptimal managementClinical pharmacyDiseaseSaudi MinistryAdultsDiagnosisConcise guidelinesGuidelinesLiterature reviewTime of writingColitisPatientsImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2021
Novel and Emerging Therapies for Inflammatory Bowel Disease
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.BooksInflammatory bowel diseaseBowel diseaseAnti-tumor necrosis factorPotential systemic manifestationsSecondary treatment failureTreatment response ratesJanus kinase inhibitorSelective Janus kinase inhibitorNew therapeutic targetsEmerging TherapiesCurrent biologicsIntestinal inflammationSystemic manifestationsUlcerative colitisCrohn's diseaseTreatment failureSafety profileNecrosis factorTherapeutic targetResponse rateDiseaseKinase inhibitorsTarget agentsInhibitorsTolerability
2019
The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis
Aniwan S, Bruining DH, Park SH, Al-Bawardy B, Kane SV, Prabhu N, Kisiel JB, Raffals LE, Papadakis KA, Pardi DS, Tremaine WJ, Loftus EV. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. Journal Of Clinical Medicine 2019, 8: 1171. PMID: 31387259, PMCID: PMC6723355, DOI: 10.3390/jcm8081171.Peer-Reviewed Original ResearchShort Inflammatory Bowel Disease QuestionnaireMayo endoscopic subscorePatient-reported outcomesUlcerative colitisClinical symptomsPatient-reported clinical symptomsChronic Illness Therapy-FatigueInflammatory Bowel Disease QuestionnaireProspective cross-sectional studyConsecutive UC patientsActivity Impairment QuestionnaireBowel Disease QuestionnaireHealth-related qualityFuture clinical trialsCross-sectional studyCombination of patientQuality of lifeStool frequencyDisease QuestionnaireEndoscopic scoreEndoscopic subscorePrimary endpointRectal bleedingUC patientsHRQoL scores
2018
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/